Celgene

BMS/Celgene merger payout evaporates as CVR deadline passes
BMS/Celgene merger payout evaporates as CVR deadline passes
Pharmaforum
Celgene
Bristol-Myers Squibb
FDA
CVRs
Flag link:
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
Flag link:
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Endpoints
Bristol-Myers Squibb
CVRs
Celgene
M&A
Flag link:
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
Zeposia
Reblozyl
Onureg
Flag link:
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
Motley Fool
Bristol-Myers Squibb
M&A
Celgene
MyoKardia
Flag link:
Celgene shareholders are parsing blurry photos in search of a payday
Celgene shareholders are parsing blurry photos in search of a payday
Stat
Celgene
Bristol-Myers Squibb
FDA
M&A
Flag link:
Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity
Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity
Xconomy
Bristol-Myers Squibb
Celgene
clinical trials
clinical trial diversity
Samit Hirawat
Flag link:
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
RAPS.org
congress
Celgene
Teva Pharmaceutical
Revlimid
Copaxone
drug pricing
Flag link:
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Fierce Pharma
drug pricing
regulatory
Celgene
Bristol-Myers Squibb
Teva Pharmaceutical
Amgen
Novartis
Mallinckrodt
AbbVie
US Congress
Flag link:
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Flag link:
Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms
Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms
Endpoints
Celgene
Antengene
IPOs
startups
Jay Mei
Hong Kong
Flag link:
AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included
AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included
Fierce Pharma
psoriasis
AbbVie
Skyrizi
Amgen
Celgene
Otezla
Flag link:
Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals
Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals
Fierce Pharma
Otzela
Celgene
Amgen
psoriasis
COVID-19
Flag link:
After Celgene deal, BMS shoots up pharma market cap rankings
After Celgene deal, BMS shoots up pharma market cap rankings
Pharmaforum
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study
Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study
BioSpace
Roche
Genentech
Tecentriq
triple negative breast cancer
clinical trials
Celgene
Abraxane
Flag link:
Bristol's Celgene merger sees it bounce Jounce drug pact
Bristol's Celgene merger sees it bounce Jounce drug pact
Fierce Biotech
Bristol-Myers Squibb
Celgene
Jounce Therapeutics
M&A
immuno-oncology
Flag link:
Bristol Myers Squibb's Zeposia launches into crowded MS market
Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
Flag link:
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Bluebird Bio
Flag link:
Amgen ramps up Otezla expansion effort with positive data in mild psoriasis
Amgen ramps up Otezla expansion effort with positive data in mild psoriasis
Fierce Pharma
Amgen
Celgene
Otezla
psoriasis
Flag link:
CHMP backs BMS’ first-in-class anemia drug Reblozyl
CHMP backs BMS’ first-in-class anemia drug Reblozyl
Pharmaforum
Bristol-Myers Squibb
EMA
CHMP
Reblozyl
anemia
Celgene
Flag link:

Pages